Earnings

EBIT and EBITDA

Earnings before interest and tax (EBIT) fell sharply, by €520.6 million, to €103.3 million in the first nine months of 2022 (Q1–Q3 2021: €623.9 million). EBIT included budgeted purchase price allocation effects amounting to an expense of €69.0 million in the first three quarters of the year (Q1–Q3 2021: expense of €63.1 million). In the reporting period, there were also non-recurring items amounting to a total expense of €38.3 million (Q1–Q3 2021: expense of €4.1 million) that essentially reflected impairment losses on assets of the Russian subsidiaries.

EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) decreased to €210.6 million (Q1–Q3 2021: €691.1 million). The adjusted EBIT margin fell sharply to 2.6 percent as a result (Q1–Q3 2021: 9.2 percent). In the third quarter, adjusted EBIT amounted to minus €101.1 million (Q3 2021: €228.9 million). This loss was primarily attributable to the rise in expected overall project costs in the SCS segment.

EBIT

in € million

Q3
2022

Q3
2021

Q1 – Q3
2022

in % of revenue

Q1 – Q3
2021

in % of revenue

EBIT

–131.2

209.1

103.3

1.3%

623.9

8.3%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

16.2

9.5

44.7

0.5%

28.4

0.4%

+ Selling expenses and administrative expenses

14.1

13.0

48.5

0.6%

42.5

0.6%

+ Research and development costs

0.1

0.0

0.1

0.0%

0.1

0.0%

+ Other costs

–0.2

–2.8

14.0

0.2%

–3.9

–0.1%

Adjusted EBIT

–101.1

228.9

210.6

2.6%

691.1

9.2%

adjusted for non-recurring items

6.2

–1.4

38.3

0.5%

4.1

0.1%

adjusted for PPA items

24.0

21.2

69.0

0.8%

63.1

0.8%

Earnings before interest, tax, depreciation, and amortization (EBITDA) stood at just €867.9 million in the reporting period (Q1–Q3 2021: €1,317.6 million). Adjusted EBITDA was also down markedly at €893.8 million (Q1–Q3 2021: €1,321.4 million), giving an adjusted EBITDA margin of 10.8 percent (Q1–Q3 2021: 17.5 percent).

EBITDA

in € million

Q3
2022

Q3
2021

Q1 – Q3
2022

in % of revenue

Q1 – Q3
2021

in % of revenue

EBITDA

128.4

443.7

867.9

10.5%

1,317.6

17.5%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

5.4

–0.0

13.8

0.2%

0.0

0.0%

+ Selling expenses and administrative expenses

0.9

1.4

10.4

0.1%

8.0

0.1%

+ Research and development costs

0.1

0.0

0.1

0.0%

0.0

0.0%

+ Other costs

–0.2

–3.2

1.6

0.0%

–4.2

–0.1%

Adjusted EBITDA

134.6

441.9

893.8

10.8%

1,321.4

17.5%

adjusted for non-recurring items

6.2

–1.9

25.9

0.3%

3.8

0.0%

adjusted for PPA items

0.0

0.0

0.0

0.0%

0.0

0.0%